| Identification | Back Directory | [Name]
Etelcalcetide HCl | [CAS]
1334237-71-6 | [Synonyms]
AMG416
AMG 416
KAI-4169
Parsabiv
Etelcalcetide HCl
AMG 416 hydrochloride
KAI-4169 hydrochloride
1262780-97-1 (free base)
velcalcetide hydrochloride
Etelcalcetide Hydrochloride
Etelcalcetide Hydrochloride (AMG-416)
AMG 416; KAI-4169; VELCALCETIDE HYDROCHLORIDE;PARSABIV;AMG416; 1262780-97-1 (FREE BASE) | [Molecular Formula]
C38H74ClN21O10S2 | [MDL Number]
MFCD32004547 | [MOL File]
1334237-71-6.mol | [Molecular Weight]
1084.71 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:10.0(Max Conc. mg/mL);8.37(Max Conc. mM)
PBS (pH 7.2):10.0(Max Conc. mg/mL);8.37(Max Conc. mM)
Water:50.0(Max Conc. mg/mL);41.87(Max Conc. mM) | [form ]
A crystalline solid | [color ]
White to off-white | [Sequence]
Ac-d-Cys（Cys）-d-Ala-d-Arg-d-Arg-d-Arg-d-Ala-d-Arg-NH2 (Disulfide bridge: Cys-Cys) |
| Hazard Information | Back Directory | [Uses]
Etelcalcetide hydrochloride (AMG 416 hydrochloride; KAI-4169 hydrochloride) is a synthetic calcimimetic as an activator of the calcium sensing receptor (CaSR). Etelcalcetide hydrochloride is effective in lowering parathyroid hormone (PTH) concentrations in patients receiving dialysis with secondary hyperparathyroidism receiving hemodialysis, which is promising for research in the field of secondary hyperparathyroidism and chronic kidney disease[1][2]. | [in vivo]
Etelcalcetide hydrochloride (2.5 μg/h and 20 μg/h, infusion, 3 days) significantly reduces plasma PTH concentrations and decreased the renal expression of Cyp24a1 with a higher delivery rate[1]. | Animal Model: | C57BL7/6J male mice | | Dosage: | 2.5 μg/h and 20 μg/h | | Administration: | infusion, 3 days | | Result: | Significantly reduced plasma PTH concentrations and unaltered Cldn14 expression with 2.5 μg/h, but decreased the renal expression of Cyp24a1 with 20 μg/h [1] |
| [storage]
Store at -20°C | [References]
[1] Differential parathyroid and kidney Ca2+-sensing receptor activation in autosomal dominant hypocalcemia 1 DOI:10.1016/j.ebiom.2022.103947
[2] Fujioka A, et al. Effect of etelcalcetide on parathyroid hormone secretion by primary hyperparathyroidism patient-derived primary parathyroid cells[J]. J Bone Miner Metab. 2021 May;39(3):396-403. DOI:10.1007/s00774-020-01158-2 |
|
|